Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) and XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.
Volatility & Risk
Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Profitability
This table compares Qualigen Therapeutics and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
| XTL Biopharmaceuticals | N/A | N/A | N/A |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.15 |
| XTL Biopharmaceuticals | $450,000.00 | 10.07 | -$1.03 million | ($0.64) | -3.22 |
XTL Biopharmaceuticals has higher revenue and earnings than Qualigen Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Qualigen Therapeutics and XTL Biopharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| XTL Biopharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Institutional and Insider Ownership
3.2% of Qualigen Therapeutics shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 1.8% of Qualigen Therapeutics shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
XTL Biopharmaceuticals beats Qualigen Therapeutics on 7 of the 8 factors compared between the two stocks.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
